Experienced Healthcare & Life Sciences Leader | Strategic Market Research | Commercial Strategy | Competitive Intelligence | Licensing & Partnership Evaluation | Market Access | Thought Leadership | AI & Data Science
Tolerability, Pricing of Oral Semaglutide Frequent Areas of Investor Debate 💊 The oral route of administration is generally preferred over injections, but dosing and tolerability could pose challenges in the real world. Nausea is the most common side effect of Oral Semaglutide, which could be a potential #challenge for an oral product. Additionally, strict dosing instructions may be difficult for some #patients to follow on a daily basis, which could impact efficacy and cause side effects 💊 On the other hand, injectable GLP-1s (TRULICITY, OZEMPIC, MOUNJARO) are now taken only once a week and are generally well-tolerated, which could potentially limit the #convenience advantage of an oral product. The #pricingstrategy is also a significant concern due to the cost of production and how it may impact the use of other Novo GLP-1s. Although data suggests that oral semaglutide is as good or better than other oral agents, the cost to produce is much higher. Oral anti-diabetic agents are generally much cheaper than injectable GLP-1s, with oral semaglutide falling somewhere between the two What are your thoughts on the tolerability and pricing of oral semaglutide? Share your insights in the comments below. #oralsemaglutide #investordebate #GLP1s #diabetesmanagement #NovoNordisk #elililly
Manager @ SUN PHARMA | Biologics, Biosimilars, Peptide Product Characterization
10moDo you have any price at par comparison with oral v/s injection!